One recent study looked at screening based on age and family history, while another looked at the effectiveness of fecal immunochemical testing with and without postpolypectomy surveillance colonoscopy.
One recent study found a link between depression and diarrhea and constipation, while another found that cognitive behavioral therapy may be an effective treatment for patients with refractory irritable bowel syndrome.
High-dose proton-pump inhibitors and aspirin appeared effective for chemoprevention in patients with Barrett's esophagus in one study, while another study found a positive association between human papillomavirus status and survival in patients with
One study found that colorectal cancer diagnosed six to 60 months after colonoscopy leads to a shorter life expectancy, while two others found increased risks of mental illness and chronic opioid use among colorectal cancer survivors.
One recent study compared postpolypectomy surveillance with colonoscopy versus fecal immunochemical testing, while another assessed the rate of postpolypectomy complications in patients prescribed antithrombotic agents.
Studies of contemporary populations with hepatitis C virus infection demonstrated that treatment with direct-acting antiviral therapies was linked to improvement in several long-term clinical outcomes.
An open-label randomized trial looked at long-term albumin administration in patients with decompensated disease, and another evaluated the use of IV albumin in hospitalized patients with cirrhosis and hyponatremia at admission.
Recent studies came to differing conclusions in their assessments of the safety of proton-pump inhibitors (PPIs), with outcomes including mortality, hepatic encephalopathy, and infections.
Studies published in July found no unfavorable association between proton-pump inhibitor (PPI) use and cognitive function.
Highlights from the conference, held this past week in San Diego, included new research and clinical tips on stopping Barrett's esophagus surveillance, diet and environmental risk factors in patients with inflammatory bowel disease, and new research